Abstract
Hematopoietic stem cell transplantation dilemma during the COVID-19 era.
Highlights
Hematopoietic stem cell transplantation Initially described in the 1950s on mice models, hematopoietic stem cell transplantation (HSCT) was first used on humans in 1957 [22,23]
The virus known as severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO with more than 2 million coronavirus cases and claiming the lives of more than 160,000 persons [2,3,4]
Droplets and close contact are the main routes of transmission, but reports suggest that transmission can occur through aerosols [6]
Summary
High-risk of disease: deferred until patient is asymptomatic and two negative PCR at least 24 h apart. Deferred for 14–21 days of last contact, or two negative PCR tests are obtained at least 1 week apartClose monitoring for symptoms. High-risk of disease: deferred for 14–21 days of last contact according to clinical judgment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
